Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 5, 2015, Pages 1259-1267

  Smorodinsky, Emmanuil ^a,b   Ansdell, David S ^a   Foster, Zeke W ^a   Mazhar, Sameer M ^a   Cruite, Irene ^a,c   Wolfson, Tanya ^a   Sugay, Sebastian B ^a   Iussich, Gabriella ^a   Shiehmorteza, Masoud ^a   Kono, Yuko ^d   Kuo, Alexander ^d   Sirlin, Claude B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic liver disease; nephrogenic systemic fibrosis

Indexed keywords

CONTRAST MEDIUM; CREATININE; GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOVERSETAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC LIVER DISEASE; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; INFLAMMATION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEVERE RENAL IMPAIRMENT; THROMBOSIS; ADVERSE EFFECTS; CHEMICALLY INDUCED; COHORT ANALYSIS; COMORBIDITY; END STAGE LIVER DISEASE; EPIDEMIOLOGY; INCIDENCE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CAUSALITY; CHILD; COHORT STUDIES; COMORBIDITY; CONTRAST MEDIA; END STAGE LIVER DISEASE; FEMALE; GADOLINIUM; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84927670032     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24650     Document Type: Article

References (38)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
2. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
3. Marckmann P, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
4. High WA, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26.
5. White GW, Gibby WA, Tweedle MF,. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272-278.
6. Sherry AD, Caravan P, Lenkinski RE,. Primer on gadolinium chemistry. J Magn Reson Imaging 2009; 30: 1240-1248.
7. FDA. U.S. Food and Drug Administration Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committee. FDA Briefing Document: Gadolinium-Based Contrast Agents & Nephrogenic Systemic Fibrosis. Dec. 8 2009; cited 2010 December. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM190850.pdf.
8. FDA. U.S. Food and Drug Administration. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMark, Magnevist, ProHance, and MultiHance. June 8 2006; cited 2010 December. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053112.htm.
9. FDA. U.S. Food and Drug Administration. Information for healthcare professionals. Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMark, Prohance). May 23, 2007; cited 2010 December. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142884.htm.
10. Mazhar SM, et al. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009; 30: 1313-1322.
11. Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
12. Sadowski EA, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
13. Kuo PH, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242: 647-649.
14. Perez-Rodriguez J, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009; 250: 371-377.
15. Prince MR, et al. Risk factors for NSF: a literature review. J Magn Reson Imaging 2009; 30: 1298-1308.
16. Foundation, N.K. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. 2002; cited 2013 11/17/2013. Available from: http://www.kidney.org/PROFESSIONALS/kdoqi/guidelines-ckd/toc.htm.
17. Radiology, A.C.o., ACR Manual on Contrast Media, Version 9. 2013.
18. Agresti A, Coull BA,. Approximate is better than "exact" for interval estimation of binomial proportions. American Statistician 1998; 52: 119-126.
19. Chiu H, et al. Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transpl 2004; 10: 465-466.
20. Saddleton E, et al. Gadolinium exposure before or after liver transplantation: no excess risk of nephrogenic systemic fibrosis (NSF)? In: Proc 19th Annual Meeting ISMRM, Montreal; 2011. p 939.
21. Zou Z, Ma L,. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol 2011; 56: 65-73.
22. Chow DS, et al. Risk of nephrogenic systemic fibrosis in liver transplantation patients. AJR Am J Roentgenol 2011; 197: 658-662.
23. Kim WR, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242.
24. Lim YS, Kim WR,. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 12: 733-746, vii.
25. Lee CU, et al. Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol 2009; 145: 1095-1102.
26. Francoz C, et al. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605-613.
27. Papadakis MA, Arieff AI,. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82: 945-952.
28. Perazella MA,. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009; 18: 519-525.
29. Thakral C, Abraham JL,. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009; 36: 1244-1254.
30. Ersoy H, Rybicki FJ,. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007; 26: 1190-1197.
31. Joffe P, Thomsen HS, Meusel M,. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491-502.
32. Tombach B, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000; 35: 35-40.
33. Morcos SK, Haylor J,. Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data. World J Radiol 2010; 2: 427-433.
34. Morcos SK, Thomsen HS,. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110: c24-31; discussion c32.
35. Edward M, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 214: 584-593.
36. Edward M, et al. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010; 256: 735-743.
37. Idee JM, et al. Clinical and biological consequences of 1 transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20: 563-576.
38. Saab G, Abu-Alfa A,. Nephrogenic systemic fibrosis-implications for nephrologists. Eur J Radiol 2008; 66: 208-212.